Peer-reviewed veterinary case report
Combining KPT-335 with chemo drugs for canine lymphoma cells
By Primarizky, Hardany et al.·Published in The Journal of veterinary medical science·2026·Joint Graduate School of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Combination effect of Exportin 1 inhibitor (KPT-335) with doxorubicin or vincristine in canine lymphoma cell lines.
- Species:
- dog
Plain-English summary
A study looked at how a new treatment called KPT-335 (Verdinexor) could help dogs with lymphoma, a type of cancer that affects the blood. Researchers tested KPT-335 alone and with two common chemotherapy drugs, doxorubicin and vincristine, on cancer cells from dogs. They found that KPT-335 helped reduce the cancer cell growth more effectively when combined with these drugs. This suggests that using KPT-335 alongside traditional treatments could be a promising option for dogs with lymphoma, especially those that are resistant to other therapies.
People also search for: dog lymphoma treatment · KPT-335 for canine cancer · doxorubicin for dog lymphoma · vincristine side effects in dogs
Abstract
Canine lymphoma is a common hematopoietic malignancy with limited therapeutic options, particularly in drug-resistant cases. Overexpression of Exportin 1 (XPO1) promotes oncogenesis by impairing the nuclear-cytoplasmic translocation of tumor suppressor proteins (TSPs). KPT-335 (Verdinexor), a selective XPO1 inhibitor, restores TSP function, inducing cell cycle arrest and apoptosis. In this study, we investigated the in vitro effects of KPT-335 alone and in combination with doxorubicin or vincristine in four canine lymphoma cell lines. KPT-335 reduced XPO1 protein expression in a dose-dependent manner, an effect reversed by proteasome inhibition, suggesting proteasome-mediated degradation. Combination treatments significantly suppressed cell proliferation compared with single agents. These findings highlight the preclinical evidence of combining KPT-335 with conventional chemotherapies in canine lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41285475/